Antiviral compounds

Abstract

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

1 - 20 . (canceled) 
     
     
         21 . A method of treating hepatitis C, said method comprising administering to a human patient a pharmaceutical composition which comprises a therapeutically effective amount of the compound 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         22 . The method of  claim 21 , further comprising administering at least one additional therapeutic agent for treating HCV to the patient. 
     
     
         23 . The method according to  claim 21 , wherein said at least one additional therapeutic agent is selected from ribavirin, an NS3 protease inhibitor, a nucleoside or nucleotide inhibitor of HCV NS5B polymerase, an alpha-glucosidase 1 inhibitor, a hepatoprotectant, a non-nucleoside inhibitor of HCV polymerase, and combinations thereof. 
     
     
         24 . The method of  claim 21 , wherein the pharmaceutical composition is a sterile injectable solution. 
     
     
         25 . The method of  claim 21 , wherein the pharmaceutical composition is a tablet. 
     
     
         26 . The method of  claim 21 , wherein the pharmaceutical composition is an oleaginous suspension.